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Abstract: Human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract
disease requiring hospitalization in infants. There are no market-approved vaccines or antiviral
agents available, but a growing number of vaccines and therapeutics are in (pre)clinical stages of
development. Reliable animal models are crucial to evaluate new vaccine concepts, but in vivo
RSV research is hampered by the lack of well-characterized animal models that faithfully mimic the
pathogenesis of RSV infection in humans. Mice are frequently used in RSV infection and vaccination
studies. However, differences in the use of mouse strains, RSV subtypes, and methodology often lead
to divergent study outcomes. To our knowledge, a comparison between different RSV inoculation
methods in mice has not been described in the literature, even though multiple methods are being
used across different studies. In this study, we evaluated various pathological and immunological
parameters in BALB/c mice after intratracheal or intranasal inoculation with RSV-A2. Our study
reveals that intranasal inoculation induces robust pathology and inflammation, whereas this is not
the case for intratracheal inoculation. As immunopathology is an important characteristic of RSV
disease in infants, these data suggest that in mice intranasal inoculation is a more appropriate method
to study RSV infection than intratracheal inoculation. These findings will contribute to the rational
experimental design of future in vivo RSV experiments.
Keywords: RSV; animal model; pathology; anesthesia; inoculation method; inflammation
1. Introduction
Respiratory syncytial virus (RSV) infection is a major cause of severe lower respiratory illness
requiring hospitalization in young infants [1]. Currently, there are no market-approved vaccines
available, although multiple vaccines are in (pre)clinical stages of development (https://www.path.
org/resources/rsv-vaccine-and-mab-snapshot/). Reliable animal models are crucial to evaluate new
vaccine concepts. Several animal models have been developed to study RSV infection and disease,
including mice, cotton rats, chimpanzees, cattle, and sheep [2,3]. However, none of these models
fully replicates the pathogenesis of RSV infection in humans. In light of this, it is pivotal to obtain a
thorough understanding of the implications of the use of different methodologies, in order to design
experimental approaches that are most suitable for answering specific research questions.
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Despite their limitations, mice are the most commonly used animal species for in vivo modeling
of RSV disease. Most inbred mouse strains, including the widely used BALB/c and C57 Bl/6 mice,
are semi-permissive for RSV infection. These mice need an inoculum with a high viral titer to detect
any lower respiratory tract disease symptoms and general measures of illness such as weight loss [4,5].
In addition, the innate and adaptive immune responses after RSV infection differ between humans and
mice. For example, mice show a limited recruitment of neutrophils to the lungs, whereas neutrophils
are the most abundant cell type during human RSV infection [4,6]. However, the availability of a vast
array of mouse-specific reagents and molecular tools makes mice indispensable for gaining mechanistic
insights into RSV infection and disease.
Not only is the translation from mouse to human difficult for RSV infection, the comparison
between mouse studies is also challenging. This is due in part to differences arising from the use of
varying mouse strains and RSV subtypes. The mouse strain is a major determinant of RSV susceptibility
and subsequent pathogenesis [7,8]. In addition, responses vary greatly between different RSV subtypes
and (clinical) isolates, even if the same mouse strain is used [9,10]. It has also been found that the
cell line used for RSV propagation and the purity of the viral inoculum influence infectivity and
pathology [11–13]. These reports highlight that appropriate selection of the study setup is crucial to
allow for proper interpretation of the results.
For multiple pathogens other than RSV, it has been suggested that different infection routes also
play a role in the inconsistent outcomes between studies. For example, both the site of pathogenesis
as well as mortality rates after influenza virus infection in ferrets differed between intranasal and
intratracheal inoculation [14,15]. Moreover, different outcomes were observed for intranasal versus
intratracheal infection of mice with Listeria monocytogenes [16] and Pseudomonas aeruginosa [17]. To our
knowledge, comparison between these inoculation methods, with regard to viral load, pathogenesis,
and the immune response has never been undertaken for RSV infection in mice. Although intranasal
inoculation methods are most common within the RSV field [18], intratracheal inoculation has also
been described [19–21].
In this study, we evaluated virus-induced pathology and the antiviral immune response in BALB/c
mice after intratracheal or intranasal inoculation with RSV-A2. Although mice in both groups received
an equal dose of the same virus stock, striking differences in viral load, lung damage, and inflammatory
mediators were apparent. Our study reveals that at three days post-infection, intranasal inoculation
results in robust pathology and immune activation, whereas intratracheal inoculation barely induces
either lung damage or inflammation. As immunopathology is an important characteristic of RSV
disease in infants, these data suggest that intranasal inoculation in mice is a more appropriate method
to mimic the effect of RSV infection in humans than intratracheal inoculation. Together, these findings
provide important insights that are essential for the rational design of future in vivo experiments
with RSV.
2. Materials and Methods
2.1. Mice
Female, specific-pathogen-free BALB/c mice (7–9 weeks old) were obtained from Charles River
Laboratories and kept at the animal facilities of Intravacc (Netherlands). The animals were allowed
to acclimatize for at least one week. Different batches of mice were used for all five experiments.
The study was approved by the Animal Ethical Committee of the Netherlands (CCD; 20185186;
April 23, 2018). All experiments were performed in accordance with the guidelines of the institutional
animal care committee.
2.2. Cells and Virus
HEp-2 cells (ATCC CCL-23) were cultured in minimum essential medium (MEM; Gibco,
Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% heat-inactivated fetal calf
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serum, and 1% penicillin/streptomycin/glycamin (Gibco). Human RSV-A2 (ATCC, VR1302) was
propagated in HEp-2 cells. The virus stock was purified between layers of 10% and 50% sucrose by
ultracentrifugation. Virus titer was determined by 50% tissue culture infective dose (TCID50) assay on
HEp2 cells. TCID50/ml was calculated using the Spearman and Karber method [22] and converted to
plaque-forming units (pfu) per mL by multiplying by 0.69.
2.3. Inoculation of Mice
Two types of experiments were performed, intratracheal inoculation and intranasal inoculation.
The intratracheal inoculation experiment was performed three times, whereas the intranasal inoculation
experiment was performed twice. All experiments were carried out on different days. Every experiment
consisted of two groups, one RSV- and one mock-infected, of three animals each. The different
experiments are indicated by distinct symbols (shape and color) in the graphs.
On day 0, mice were intratracheally or intranasally infected with live, sucrose-purified RSV-A2.
Preceding intratracheal inoculation, mice received an intraperitoneal injection of ketamine/xylazine
(80 and 10 mg/kg, respectively). Mice were subsequently infected via a cannula in the trachea
with 2 × 106 pfu RSV-A2 diluted in phosphate buffered saline (PBS) in a total volume of 50 µL.
Before intranasal inoculation, mice received anesthesia through inhalation of isoflurane (3.5% in O2).
Mice were then infected with 2 × 106 pfu RSV-A2 diluted in PBS in a total volume of 50 µL, which was
administered dropwise to the nose. A schematic representation of the inoculation techniques is shown
in Figure 1A. Control animals were mock inoculated either intratracheally or intranasally with 50 µL
PBS containing 10% sucrose.
2.4. Sample Collection
Three days post-infection (dpi), mice were euthanized by exsanguination under isoflurane
anesthesia. Bronchoalveolar lavage (BAL) samples and lungs were collected and processed as
described below. Weights were measured daily during the course of the experiment.
BAL samples were obtained by infusing 0.8 mL or 0.9 mL (depending on weight of the animal)
PBS into the lungs via the trachea, followed by aspiration into a syringe. The BAL sample was
centrifuged at 500× g for 5 min. Cell pellets were collected for flow cytometric analysis and the
supernatant was snap-frozen and stored at −80 ◦C for subsequent analysis of cytokine/chemokine and
albumin concentrations.
Single-cell suspensions were prepared from mouse lungs by digestion with collagenase and
DNase (Sigma-Aldrich, Saint Louis, MO, USA). Cells were pushed through 70 µm cell strainers and
erythrocytes were lysed with ammonium-chloride-potassium (ACK) lysis buffer (0.155 M NH4CL,
10 mM KHCO3, and 0.1 mM Na2EDTA). Lung cells were used for determination of the viral load.
2.5. Viral Load
The amount of viral RNA was used as a proxy for viral load and was determined by quantitative
reverse transcriptase PCR (RT-qPCR). Total RNA was extracted from lung single-cell suspensions
using a Nucleospin RNA extraction kit (Machery-Nagel, Düren, Germany) and quantified on a Qubit
fluorimeter (Invitrogen, Thermo Fisher Scientific). Subsequently, cDNA was synthesized using an
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) on a thermal cycler (ABI GeneAmp 9700,
Applied Biosystems, Thermo Fisher Scientific). Finally, qPCR was performed on a real-time PCR
machine (Applied Biosystems StepOne Plus) using SYBR Green reagents (Bio-Rad) and RSV-specific
primers. Resulting CT values were converted to arbitrary units (AU) using a standard curve.
Amplification with primers corresponding to mouse actin mRNA was performed in parallel and used
for normalization. Primer sequences are detailed in Table 1.
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negative for RSV after intratracheal inoculation (depicted in panel B) were excluded from further 
analysis and removed from panel C. Geometric mean and SD are depicted. Viral load was log 
transformed before statistical comparison between the two groups was performed using an unpaired 
Student’s t-test (*p < 0.05). (D) Albumin concentration in the bronchoalveolar lavage (BAL) fluid 
measured by ELISA. Albumin concentrations were log transformed before analysis by a one-way 
ANOVA, followed by Tukey’s multiple comparisons test. Geometric mean and SD are depicted. (E) 
Mouse body weight with the weight at day 0 set to 100%. Each data point represents the mean weight 
(+/- SD) of all mice from the indicated group: mock intratracheal (IT) (n = 9), RSV IT (n = 7), mock 
intranasal (IN) (n = 6), RSV IN (n = 6). Body weights of mock- and RSV-infected animals were 
Figure 1. Viral load and pathology following intratracheal or intranasal respiratory syncytial virus (RSV)
infection. Mice were (mock) inoculated either intratracheally or intranasally with 2 × 106 pfu of live
RSV-A2 or vehicle control. (A) Schematic figure of the intratracheal and intranasal inoculation methods.
(B,C) Viral load in mouse lung cells as determined by RT-qPCR. Two animals that tested negative for
RSV after intratracheal inoculation (depicted in panel B) were excluded from further analysis and
removed from panel C. Geo etric mean and SD are depicted. Viral load was log transformed before
statistical comparison between the two groups was performed using an unpaired Student’s t-test
(* p < 0.05). (D) Albumin concentration in the bronchoalveolar lavage (BAL) fluid measured by ELISA.
Albumin concentrations were log tra sformed before analysis by a one-way ANOVA, followed by
Tukey’s multiple comparisons test. Geometric mean and SD are depicted. (E) Mouse body weight with
the weight at day 0 set to 100%. Each data point represents the mean weight (+/- SD) of all mice from
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the indicated group: mock intratracheal (IT) (n = 9), RSV IT (n = 7), mock intranasal (IN) (n = 6), RSV IN
(n = 6). Body weights of mock- and RSV-infected animals were compared using a two-way ANOVA,
followed by Sidak’s multiple comparisons test. Only the IN inoculation groups showed a difference
between mock- and RSV-inoculated animals (* p < 0.05). Mice from separate experiments are indicated
with a distinct symbol (IT: white/gray/black circles; IN: white/black squares). Abbreviations: AU,
arbitrary units; BAL, bronchoalveolar lavage; IN, intranasal; IT, intratracheal; KX, ketamine-xylazine;
LRT, lower respiratory tract; RSV, respiratory syncytial virus; SD, standard deviation; URT, upper
respiratory tract.
Table 1. Primer sequences.
Transcript Sequence
RSV N Forward: 5′-TGACAGCAGAAGAACTAGAGGC-3′
Reverse: 5′-TGGGTGATGTGAATTTGCCCT-3′
Mouse Actin Forward: 5′-CGGTTCCGATGCCCTGAGGCTCTT-3′
Reverse: 5′-CGTCACACTTCATGATGGAATTGA-3′
2.6. Flow Cytometric Analysis of Immune Cell Subsets in the BAL
BAL cells were isolated as described above and incubated with anti-mouse CD16/CD32 Fc receptor
block (BD Pharmingen, BD Biosciences, San Jose, CA, USA) at 1 µg per 2 × 106 cells for 10 min at 4 ◦C.
Cells were subsequently incubated with the following antibodies: CD3-Pacific Blue (17A2, Biolegend,
San Diego, CA, USA), CD4-APC (RM4-5, BD Pharmingen), CD8a-PE (53-6.7, Biolegend, Biolegend),
CD11b-BV711 (M1/70, Biolegend), CD19-BV510 (1D3, BD Horizon, BD Biosciences), CD41-PE-CY7
(MWReg30, Biolegend), CD45-BUV395 (30-F11, BD Horizon), NKp46-BV605 (29A1.4, Biolegend), and
Ly-6G-PE/Dazzle (1AB, Biolegend). Ultimately, cells were fixed in 3.7% paraformaldehyde in PBS for
10 min before flow cytometric analysis using an LSR Fortessa ×20 (BD Biosciences). FlowJo software
V10 (FlowJo, BD, Franklin Lakes, NJ, USA) was used for data analysis. The gating strategy for one
representative BAL sample is depicted in Supplementary Figure S1.
2.7. Albumin and Cytokine/Chemokine Determination in BAL Fluid
Albumin concentrations were determined using a mouse albumin ELISA (ICL, Portland, OR,
USA), according to the manufacturer’s protocol. Cytokine/chemokine concentrations in BAL samples
were analyzed using the mouse anti-virus response panel LEGENDplex (Biolegend), according to the
manufacturer’s protocol. This assay contained the following cytokines/chemokines: CCL2 (MCP-1),
CCL5 (RANTES), CXCL1, CXCL10 (IP-10), IFN-α, IFN-β, IFN-γ, IL-1β, IL-6, IL-10, IL-12, GM-CSF,
and TNF.
2.8. Statistical Methods
All statistical analyses were performed with Prism 7 (GraphPad Software, San Diego, CA, USA).
Viral load, albumin concentrations, cell counts, and cytokine/chemokine concentrations were log
transformed before statistical testing. Comparisons between two groups were performed using an
unpaired Student’s t-test. Multiple comparisons were analyzed using a one-way analysis of variance
(ANOVA), followed by Tukey’s multiple comparisons test. Differences in mouse body weight between
mock- and RSV-inoculated animals were analyzed using a two-way ANOVA, using the day and
group as variables, followed by Sidak’s multiple comparisons test. p values <0.05 were considered
statistically significant.
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3. Results
3.1. Intranasal Inoculation Results in Slightly Higher Viral Load and More Pronounced Pathology Compared to
Intratracheal Inoculation
To compare the effect of the inoculation method on viral load and pathology, BALB/c mice were
(mock) infected with vehicle control or RSV-A2 either intratracheally (n = 9 per group, divided over
three experiments) or intranasally (n = 6 per group, divided over two experiments). We pooled all data
per group for subsequent analysis. Separate experiments are indicated in the graphs by distinct shapes
and colors of symbols. The technical differences between intratracheal and intranasal inoculation are
illustrated in Figure 1A.
The viral load was determined at three dpi by assessing the amount of viral RNA in total lung
cells using RT-qPCR. The results showed a higher mean lung viral load in intranasally inoculated
compared to intratracheally inoculated animals (Figure 1B). Whereas all intranasally infected animals
tested positive for viral RNA in the lungs, two animals that had been intratracheally inoculated tested
negative for viral RNA. This suggests that intratracheal inoculation is more error-prone than intranasal
inoculation, which is likely due to the possibility of inadvertent administration of the inoculum into the
esophagus. The two RSV-negative animals were excluded from all further analysis. Upon exclusion of
these two animals, the mean viral load was approximately 2-fold higher in the intranasally compared
to the intratracheally inoculated animals, which was a statistically significant difference (Figure 1C).
No virus was detected in any of the mock-inoculated animals.
To determine whether the high viral load upon intranasal inoculation was accompanied by
more pronounced pathology in the lung, we subsequently quantified the albumin concentration in
the bronchoalveolar lavage (BAL) fluid and assessed changes in body weight during the course of
the experiment. Leakage of serum albumin from the circulation into the lung lumen can be used
as a measure for lung damage [23]. Although intratracheal RSV inoculation did not result in any
observable lung damage, with albumin concentrations comparable to those of mock inoculation,
intranasal inoculation with RSV resulted in higher albumin concentrations compared to both intranasal
mock inoculation and intratracheal RSV inoculation, although this was not statistically significant
(Figure 1D). In addition to lung damage, animals that had received RSV through intranasal inoculation
showed a decrease in body weight, losing almost 5% of body weight at day 1 (Figure 1E). In contrast,
animals that had received an intratracheal inoculation did not show a decrease in body weight, but
rather gained weight throughout the experiment. Intranasally mock-inoculated animals did not show
a change in body weight.
3.2. Virus-Induced Pulmonary Cellular Influx is More Pronounced Upon Intranasal Compared to
Intratracheal Inoculation
To investigate the effect of inoculation method on inflammatory parameters, we assessed
pulmonary cellular influx by determining (specific) immune cell counts in the BAL at three dpi
by flow cytometry. The total leukocyte count in the BAL was significantly increased upon RSV
infection compared to that of mock infection for both inoculation methods (Figure 2A). In addition,
total leukocyte counts were significantly higher upon intranasal RSV inoculation compared to those
of intratracheal RSV inoculation. Cell type-specific analysis revealed that natural killer (NK) cell,
neutrophil, antigen-presenting cell (APC), and CD4 and CD8 T cell counts were increased upon
RSV infection compared to those of mock infection for both inoculation methods (Figure 2B–F).
These differences were statistically significant, except for neutrophils. In addition, NK cell, neutrophil,
APC, and CD4 and CD8 T cell counts were markedly higher upon intranasal compared to intratracheal
RSV inoculation. These differences were statistically significant, except for CD4 T cells. No increased
B cell counts were detected after intratracheal or intranasal RSV inoculation in the BAL at three dpi.
These data indicate that the observed pulmonary influx is composed of a variety of immune cells
and does not appear to be linked to influx of one particular cell type. Overall, we found that at three
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dpi the pulmonary cellular influx in the BAL induced by intranasal RSV inoculation was much more
pronounced than that induced by intratracheal RSV inoculation.Viruses 2019, 11, x FOR PEER REVIEW 7 of 12 
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Figure 2. Pul onary cellular influx follo ing intratracheal or intranasal S infection. ice ere
(mock) inoculated either intratracheally or intranasally ith 2 × 106 pfu of live RS - 2 or vehicle
control. Cells were isolated from the bronchoalveolar lavage (BAL) and analyzed using flow cytometry.
Mice from individual experiments are indicated with a distinct symbol (IT: white/gray/black circles;
IN: white/black squares). Graphs depict absolute cell counts for: (A) total leukocytes (CD45+), (B) NK
cells (CD3-, C 56+), (C) neutrophils (CD3-, Ly-6G+, CD11b+), (D) antigen-presenting cells (CD3-,
Ly-6G-, CD11b+), (E) CD4 T cells (CD3+, C 4+), and (F) CD8 T cells (CD3+, CD8+). All graphs depict
geometric mean and SD. Cell count data were log transformed before analysis with a one-way ANOVA,
followed by Tukey’s multiple comparisons test (* p < 0.05, ** p < 0.01, *** p < 0.001). Abbreviations:
APCs, antigen-presenting cells; BAL, bronchoalveolar lavage; IN, intranasal; IT, intratracheal; NK cells,
natural killer cells; RSV, respiratory syncytial virus; SD, standard deviation.
3.3. Elevated Virus-Induced Pulmonary Cellular Influx upon Intranasal Inoculation is Accompanied by
Increased Cytokine and Chemokine Levels
The influx of immune cells in the lungs is a hallmark of inflammation and is often accompanied
by an increase in the levels of (pro-inflammatory) cytokines and chemokines. To investigate whether
intranasal inoculation results in elevated secretion of soluble pro-inflammatory mediators compared to
intratracheal inoculation, we determined the concentration of various cytokines and chemokines in the
BAL fluid at three dpi. We focused on soluble mediators that are known to be involved in the response
against viral infection.
Compared to mock infection, RSV infection via both inoculation methods resulted in increased
BAL concentrations of CCL2 (MCP-1), CCL5 (RANTES), CXCL1, CXCL10 (IP10), IFN-α, IFN-γ, and
TNF (Figure 3A–G). These differences were statistically significant, except for CCL5 and IFN-α in the
case of intratracheal inoculation. IL-1β, IL-12, and GM-CSF showed no difference upon RSV infection
compared to mock infection and the levels of IFN-β, IL-6, and IL-10 remained below the limit of
detection. Compared to intratracheal RSV inoculation, mice that had been intranasally inoculated
with RSV showed 3- to 8-fold higher levels of CCL2, CCL5, CXCL1, CXCL10, IFN-α, IFN-γ, and TNF
(Figure 3H). These differences were all statistically significant. Similar to the pulmonary cellular influx,
we observed differences in some of the pro-inflammatory mediators between experiments performed
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on different days. In summary, RSV infection induced expression of a number of pro-inflammatory
cytokines and chemokines. Animals that were inoculated intranasally showed markedly higher levels
of RSV-induced pro-inflammatory mediators in BAL fluid than intratracheally inoculated animals at
three dpi.
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Figure 3. Cytokine and chemokine levels in the bronchoalveolar lavage following intratracheal or
intranasal RSV infection. Mice were (mock) inoculated either intratracheally or intranasally with 2 × 106
pfu of live RSV-A2 or vehicle control. Bronchoalveolar lavage (BAL) fluid was analyzed at three dpi using
a multiplex mouse anti-virus response panel immunoassay. (A–G) Concentrations in pg/Ml of CCL2,
CCL5, CXCL1, CXCL10, IFN-α, IFN-γ, and TNF. Mice from individual experiments are indicated with
a distinct symbol (IT: white/gray/black circles; IN: white/black squares). Cytokine concentrations were
log transformed before analysis with a one-way ANOVA, followed by Tukey’s multiple comparisons
test (** p < 0.01, *** p < 0.001). (H) Concentration of indicated soluble pro-inflammatory mediators after
either intratracheal (black bars) or intranasal (gray bars) RSV infection. The bars represent the geometric
mean and SD of all animals belonging to the indicated groups. Fold change between intratracheal
and intranasal infection is indicated above each pair of bars. Abbreviations: BAL, bronchoalveolar
lavage; CCL, CC chemokine ligand; CXCL, CXC chemokine ligand; IN, intranasal; IP10, interferon
gamma-induced protein 10; IT, intratracheal; MCP-1, monocyte chemoattractant protein 1; RANTES,
Regulated upon Activation, Normal T cell Expressed and presumably Secreted; RSV, respiratory
syncytial virus; SD, standard deviation.
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4. Discussion
Seemingly minor methodological differences can have profound effects on the outcome of animal
studies. It is therefore of pivotal importance to understand beforehand the implications of choosing
a particular method, in order to allow for proper interpretation of the results obtained at the end of
the experiment. In the present study, we compared the pathological and immunological effects of
RSV infection via intratracheal or intranasal inoculation. The latter resulted in a slightly higher viral
load that was accompanied by more pronounced pathology compared to intratracheal inoculation.
In addition, inflammatory parameters such as pulmonary cellular influx and pro-inflammatory cytokine
and chemokine levels were significantly higher after intranasal versus intratracheal inoculation.
A possible explanation for the observed differences in viral load, pathology, and host responses
is the difference in (primary) infection site between intratracheal and intranasal inoculation.
During intratracheal inoculation, the virus is delivered directly to the lung, presumably resulting in
an infection that is confined to the lower respiratory tract, at least initially. In contrast, intranasal
inoculation with the volume used in this study results in infection of both the upper and lower
respiratory tract [24]. It is conceivable that viral replication in the upper airways contributes to a higher
viral load in the lungs. In addition, it is likely that the host response to viral infection in the upper
airways influences the immune response in the lower airways. Previous studies have shown that viral
replication and host responses may vary depending on the anatomical localization of the RSV infection.
For example, in vitro studies have shown increased viral production in human nasal epithelial cells
compared to bronchial epithelial cells [25]. In contrast, ex vivo studies with primary pediatric epithelial
cell cultures have shown lower RSV titers accompanied by slightly lower cytokine responses in nasal
cells compared to bronchial cells [26]. Interestingly, influenza virus infection in ferrets resulted in higher
mortality rates after intratracheal inoculation compared to intranasal inoculation [15]. These findings
highlight that virus-specific information on the outcomes of different inoculation routes is essential for
the design of future studies.
Another important factor that might have contributed to the observed differences is the differential
use of anesthetics between the two inoculation methods. For intratracheal inoculation, which is a
more invasive procedure, the induction of anesthesia through ketamine/xylazine injection is common
practice. Intranasal inoculation only requires a short duration of anesthesia and is therefore performed
under inhaled isoflurane anesthesia. Although not specifically investigated for RSV infection, the use
of anesthetics can have a major impact on the immune system [27–30]. Multiple studies have reported
that ketamine possesses anti-inflammatory properties and impairs the release of pro-inflammatory
cytokines [29,31,32]. In addition, ketamine has been shown to have antiviral properties against rabies
virus [33]. Although isoflurane has also been shown to reduce inflammation, these effects were mostly
seen after long-term exposure [30,34,35]. Taken together, the use of ketamine/xylazine anesthesia
for intratracheal inoculation may, at least in part, explain the observed lower immunopathology
compared to intranasal inoculation. Considering this, we found it striking that a considerable number
of published studies fail to specify the type of anesthesia that was used during RSV infection in mice.
The main limitation of our study is the fact that the intratracheal and intranasal inoculations
were performed in separate experiments, which is a suboptimal experimental setup to compare the
two methods. However, during each experiment, exactly the same virus dose was used, originating
from the same virus batch. In addition, all animals were obtained from the same source, were of
similar age, and were handled at the same facility. Nevertheless, we did observe differences between
experiments performed on different days, especially regarding the immunological read-outs. As we
used female mice for our study, a possible explanation for these effects is the ovarian cycle of the
different batches of animals. Multiple studies have shown differences in the immune response between
the different ovarian cycle phases [36,37]. For future experiments, the use of male mice might be more
appropriate. However, this phenomenon also highlights the importance of performing experiments on
multiple days to control for these kinds of variations. Taken together, we believe the experimental
conditions of our study were similar enough to warrant a comparison between the two inoculation
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methods, especially considering the fact that the observed differences are quite striking and may have
implications for the choice of inoculation method for future animal experiments.
Another limitation of our study is the fact that most pathological and immunological parameters
were only assessed at one time-point post infection. It is possible that the observed differences are due to
variations in the kinetics of virus replication and host response depending on the site of initial infection
and/or anesthesia. However, the absence of a change in body weight upon intratracheal inoculation
suggests this is not the main cause underlying the observed effects. Notably, we only assessed the
short-term consequences of viral infection on pathology and host response. It remains a possibility
that long-term immune responses, such as humoral and cellular memory responses, are differently
affected by the two inoculation methods. Nevertheless, when focusing on these short-term responses,
intranasal inoculation appears to be the method of choice.
In conclusion, we have demonstrated striking differences between intratracheal and intranasal
RSV inoculation with regards to pathological and immunological read-outs, which may be explained
by differences in the (initial) site of infection or the differential use of anesthetics. Based on our findings,
intranasal inoculation appears to be better suited to the study of RSV-induced immunopathology than
intratracheal inoculation. Not only does intranasal inoculation more accurately mimic the natural
route of infection, it is also a less invasive procedure, requires milder anesthetics, is less error-prone,
and, as we have demonstrated, induces more pronounced pathology and immune responses than
intratracheal inoculation. Although it remains to be investigated whether the route of administration
or the anesthetic is the main factor underlying the observed differences, it is evident that the selection
of inoculation method (even when both techniques deliver the virus to the lower respiratory tract) is of
crucial importance to obtain the most appropriate model to mimic RSV disease in humans.
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